Wednesday 4th November – Day 1 Main ConferenceWednesday, 4 November 2026 - GMT (Greenwich Mean Time, GMTZ)

Gain an insight into some of the most cutting- edge technology and services hitting today’s Cell & Gene Therapies market through a series of 10-minute product demos live at the exhibit booths.

Two decades ago, NanoEntek introduced the world’s first automated cell counter. Today, the EVE HT FL and EVE HT A26 bring true high-throughput counting to cell and gene therapy, combining speed, accuracy and full walk-away automation for CGT process development, manufacturing and QC. Join our live demo to see the EVE HT A26 in action.

Join us at our 10-minute presentation at our booth to discover how NanoFCM’s single-particle analysis technology can provide deeper insights into the quality and heterogeneity of lipid nanoparticles (LNPs), lentiviral vectors (LVVs) and other nanoparticles. Find out how multiparameter characterization can reveal important features such as particle size, concentration, payload encapsulation, copy number and ligand marker expression per particle, and how it can identify distinct subpopulations that conventional bulk methods might miss. These insights can support the optimization of formulations, the development of processes and the assessment of quality, helping to advance the development of LNP-based therapeutics and viral vector applications.

• What is the single biggest milestone the exosome field must achieve by 2028 to maintain investor and pharma confidence?
• Native secretomes vs. engineered targeted vesicles: Which path crosses the clinical finish line first?
• Learning from the cell therapy playbook: How do we avoid the 20-year translational lag that plagued early MSCs?
• What will finally convince Big Pharma to commit to major licensing deals?
• Defining convincing clinical endpoints when exosome therapeutics operate across multiple biological mechanisms at once.